COVID-19 Clinical Trial
Official title:
A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients
The purpose of this study is to assess the ability of regular gargling to eliminate severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the throat and nasopharynx. This 4
arms interventional study compares the effect of gargling using povidone-iodine, essential
oils- based, tap water with control (no intervention) among Stage 1 coronavirus disease-2019
(COVID-19) patients.
Findings from this study will provide new insight into the importance of gargling in the
treatment and prevention of COVID-19.
Experimental plan
After consent is taken, all groups will be briefed regarding the study protocol separately.
- Group A will be briefed on the correct procedures of gargling with Betadine®. The
participants will be instructed to take 10ml of povidone-iodine (PVP-I), tilt their
heads backward and gargle for 30 seconds, three times per day for 7 days
- Group B will be briefed on the correct technique of gargling with Listerine®. The
participants will be instructed to take 20ml of essential oils, tilt their heads
backward and gargle for 30 seconds, three times per day for 7 days
- Group C will be briefed on the correct technique of gargling with hydrogen peroxide. The
participants will be instructed to take 10ml of hydrogen peroxide, tilt their heads
backward and gargle for 30 seconds, three times per day for 7 days
- Group D will be briefed about the involvement in this study. They will be managed
according to the standard protocol of the hospital with no additional intervention.
Monitoring
1. Oropharyngeal and nasopharyngeal swabs will be taken on day 4, 6 of intervention, and
day 12 post-intervention. The swabs will be subjected to detection of SARS-CoV-2 by
real-time reverse transcriptase-polymerase chain reaction (rt RT-PCR).
2. Patients will be given a chart for them to record their gargling practice and symptoms
(if any) during the intervention period ( 7 days)
3. Clinical data collection sheet will be provided to attending clinicians. The required
information includes demographic data, daily vital signs, serial absolute lymphocytic
count, LDH, chest radiograph, and symptoms. Clinical monitoring will be done until day
14 of the intervention.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|